Compare WIA & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIA | SENS |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.4M | 213.2M |
| IPO Year | N/A | 2014 |
| Metric | WIA | SENS |
|---|---|---|
| Price | $8.16 | $5.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | 59.4K | ★ 995.5K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $7.95 | $0.41 |
| 52 Week High | $8.54 | $8.75 |
| Indicator | WIA | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 58.81 | 46.62 |
| Support Level | $8.09 | $5.41 |
| Resistance Level | $8.29 | $8.55 |
| Average True Range (ATR) | 0.07 | 0.46 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 76.47 | 41.92 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.